---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005658"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:39:59.548320+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus discontinues AB-161 and coronavirus programs, focuses on HBV; cash runway extended to Q3 2025

## Summary
- Discontinuing AB-161 (oral RNA destabilizer) due to pre-clinical toxicology finding; no safety issues in Phase 1 single doses.
- Discontinuing coronavirus combination therapy (AB-343) due to unfavorable PK profile in IND-enabling studies.
- Dosed first subject in Phase 1a/1b for oral PD-L1 inhibitor AB-101; preliminary data expected H1 2024.
- Pipeline changes expected to extend cash runway through Q3 2025.
- Ongoing LNP patent litigations against Moderna (claim construction hearing Feb 2024) and Pfizer/BioNTech.

## SEC filing metadata
- accession: 0001171843-23-005658
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323005658/0001171843-23-005658-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323005658/f8k_091123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005658
- JSON: https://secwatch.observer/filing/0001171843-23-005658.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005658.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.